Article Details

Glofitamab shows 'curative potential' in relapsed/refractory diffuse large B-cell lymphoma

Retrieved on: 2022-12-11 23:28:29

Tags for this article:

Click the tags to see associated articles and topics

Glofitamab shows 'curative potential' in relapsed/refractory diffuse large B-cell lymphoma. View article details on hiswai:

Excerpt

... Kite Pharma, Novartis and Roche. Hutchings reports consultant/advisory/board of directors roles with and/or research funding from AbbVie, ...

Article found on: www.healio.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up